In:
Tumori Journal, SAGE Publications, Vol. 101, No. 3 ( 2015-05), p. e96-e98
Abstract:
First-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for patients with advanced non-small cell lung cancer who were selected on the basis of EGFR mutations have improved the progression-free survival with acceptable toxicity compared to standard chemotherapy. However, acquired resistance to EGFR-TKIs has been identified as an important clinical problem. Transformation to small cell lung cancer (SCLC) is a rare mechanism of resistance to EGFR-TKI therapy. We describe the case of a 61-year-old man who presented transformation from adenocarcinoma to SCLC as the manifestation of acquired resistance after EGFR-TKI treatment. He underwent chemotherapy with etoposide and cisplatin and achieved a complete response.
Type of Medium:
Online Resource
ISSN:
0300-8916
,
2038-2529
Language:
English
Publisher:
SAGE Publications
Publication Date:
2015
detail.hit.zdb_id:
280962-X
detail.hit.zdb_id:
2267832-3
Permalink